Rosen Law Firm Urges Applied Therapeutics Investors to Act Before February 18 Deadline

NEW YORK, February 11, 2025 (GLOBE NEWSWIRE) --

WHY: The Rosen Law Firm, known globally for its focus on investor rights, is reminding those who purchased securities of Applied Therapeutics, Inc. (APLT) from January 3, 2024, to December 2, 2024 (the "Class Period"), about the critical lead plaintiff deadline on February 18, 2025.

SO WHAT: Investors who bought Applied Therapeutics securities within the designated Class Period may be eligible for compensation without incurring any upfront costs, as legal fees are managed through a contingency fee arrangement.

WHAT TO DO NEXT: To participate in the class action lawsuit against Applied Therapeutics, you can visit this link or contact Phillip Kim, Esq. at 866-767-3653 or via email at [email protected]. It is important to note that a class action lawsuit has already been initiated. Should you wish to be the lead plaintiff, it is necessary to notify the court by February 18, 2025. Taking on the role of lead plaintiff signifies that you will represent other class members in the lawsuit.

WHY ROSEN LAW: Investors are encouraged to choose legal counsel that is experienced and has a proven history of success, especially in leading roles in notable cases. Many firms that issue notices may lack the same level of experience, resources, or recognition as the Rosen Law Firm. Notably, several firms act merely as intermediaries and do not handle the actual litigation themselves. The Rosen Law Firm has a strong reputation for representing investors internationally, particularly in securities class actions and shareholder derivative litigation. The firm has achieved significant settlements, including one of the largest securities class action settlements against a Chinese company. In fact, it was ranked No. 1 by ISS Securities Class Action Services for the most securities class action settlements in 2017 and has consistently ranked in the top four since 2013, recovering hundreds of millions of dollars for investors.

CASE DETAILS: The lawsuit alleges that statements made by Applied Therapeutics during the Class Period were misleading and concealed vital information regarding the clinical trial protocols and practices being used. Therefore, investors were misled into believing that appropriate clinical practices were being followed. The complaint asserts that the company was not, in fact, adhering to proper clinical trial protocols, thereby increasing the risk that the trial data would be rejected by the U.S. Food and Drug Administration (FDA) when a New Drug Application was submitted. Once the true nature of the situation was revealed to the market, investors experienced significant financial losses.

If you wish to join the class action regarding Applied Therapeutics, please visit this page, or reach out to Phillip Kim, Esq. via telephone at 866-767-3653 or email [email protected].

Note that no class has yet been certified. Until certification, you are not represented by legal counsel unless you retain one yourself. You may select your own counsel, or you may choose to remain an inconspicuous class member and take no action at this time. Your right to share in any potential recovery is not contingent upon being a lead plaintiff.

Stay connected for updates on LinkedIn, Twitter, or Facebook.

Attorney Advertising. Past results do not guarantee similar outcomes.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

lawsuit, investors, AppliedTherapeutics